Approved for use through 07/31/2006. OMB 0651-0032

Under the Pa	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE pperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless if displays a valid OMB control number.
DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN	
APPLICATION DATA SHEET (37 CFR 1.76)	
Title of Invention	Aminopyrazole Derivatives As GSK-3 Inhibitors
As the below named inventor(s), I/we declare that:	
This declaration is directed to:	
	The attached application, (and Preliminary Amendment, if applicable), or
	Application No. 10/580,615 and PCT/IB04/03749, filed on November 15, 2004
	as amended on (if applicable);
I/we believe the sought;	at I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is
I/we have revie amendment sp	wed and understand the contents of the above-identified application, including the claims, as amended by any edifically referred to above;
Iwe acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me'us to be material to patentability as defined in 3 T CPR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.	
WARNING	
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identify thet. Personal information such as social security numbers, bank account numbers, or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application if this type of personal information is included in documents submitted to USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (nuless a non-publication request in compliance with 3 CFR 1.13/a) is made in the application or application and papilication application and authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.	
All statements made herein of my/own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.	
Full Name of Inventor(s)	
Inventor 1	Daniel W. Kung
Signature	Deput Wy Citizen of US  Date   S Mary 2007
Additional inventors are being named on	

Burden Hour Statement: This collection of information is required by 35 U.S.C. 115 and 37 GFR 1.63. The information is used by the public to file (and the PTO to process) an application. Confidentiatity is governed by 36 U.S.C. 122 and 37 GFR 1.14. This form is estimated to take 1 minute to complete. This time will vary depending unor the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief information Officer, U.S. Patient and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patient's Washington, DC 20231.